"目录号: HY-14268
Metabolic Enzyme/Protease-
Febuxostat(TEI 6720;TMX 67 )是选择性黄嘌呤氧化酶（XO）抑制剂，Ki为0.6 nM。
Xanthine Oxidase
相关产品
Allopurinol-Topiroxostat-Baicalein-Benzbromarone-Febuxostat D9-Phytic acid-
生物活性
Description
Febuxostat(TEI 6720;TMX 67 ) is selective xanthine oxidase inhibitor with Ki of 0.6 nM.IC50 value: 0.6 nM (Ki) [1]Target: xanthine oxidasein vitro: Febuxostat displays potent mixed-type inhibition of the activity of purified bovine milk xanthine oxidase, with Ki and Ki' values of 0.6 nM and 3.1 nM respectively, indicating inhibition of both the oxidized and reduced forms of xanthine oxidase [1]. in vivo: Febuxostat (5–6 mg/kg/day) combined with fructose significantly lowers blood pressure, UA, triglycerides, and insulin in rats compared with fructose alone. Febuxostat (5–6 mg/kg/day) combined with fructose also reduces glomerular pressure, renal vasoconstriction, and afferent arteriolar area in rats compared with fructose alone [2]. Febuxostat prevents hyperuricemia in 5/6 nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) rats and ameliorates proteinuria, preserves renal function and prevents glomerular hypertension in both 5/6 nephrectomy (5/6 Nx)+vehicle (V)+Febuxostat(Fx) and 5/6 nephrectomy (5/6 Nx)+oxonic acid (OA)+Febuxostat(Fx) groups [3]. Febuxostat (5 mg/kg/d by gavage for 8 days) treatment after transverse aortic constriction (TAC) attenuates the TAC-induced left ventricular (LV) hypertrophy and dysfunction. Febuxostat blunts the TAC-induced increases in nitrotyrosine (indicating reduced myocardial oxidative stress), p-Erk(Thr202/Tyr204), and p-mTOR(Ser2488), with no effect on total Erk or total mTOR [4].
Clinical Trial
NCT01701622
University of Mississippi Medical Center
Blood Pressure-Gout
January 2010
NCT01763996
Takeda
Coronary Artery Disease
May 2013
Phase 4
NCT01350388
University of Utah-Takeda
Chronic Kidney Disease-Diabetes
May 2011
NCT01078389
Takeda
Joint Damage
March 2010
Phase 2
NCT01082640
Takeda
Renal Impairment
April 2010
Phase 2
NCT00995618
Nuon Therapeutics, Inc.
Gout-Hyperuricemia
September 2009
Phase 2
NCT01496469
Takeda
Hypertension
February 2012
Phase 2
NCT01549977
Takeda
Angina
July 2012
Phase 2
NCT01883167
Ardea Biosciences, Inc.
Healthy
June 2013
Phase 1
NCT02374164
Takeda
Gout
February 2015
Phase 1
NCT01984749
Freed Study Group-Teijin Pharma
Hyperuricemia
November 2013
NCT02279342
Yokohama City University Medical Center
Coronary Artery Disease
October 2014
Phase 4
NCT01724528
Menarini Group
Tumor Lysis Syndrome
October 2012
Phase 3
NCT01472692
University of California, San Diego
Prehypertension-Gout-Pulse Wave Velocity-Hypertension-24 Hour Blood Pressure
October 2011
Phase 4
NCT02579096
VA Office of Research and Development
Gout-Chronic Kidney Diseases
March 6, 2017
Phase 4
NCT02504320
Takeda
Healthy Volunteers
August 2015
Phase 1
NCT03131583
Jiangsu HengRui Medicine Co., Ltd.
Gout
February 17, 2017
Phase 1
NCT00102440
Takeda
Gout
July 2002
Phase 3
NCT02752633
Landspitali University Hospital-Mayo Clinic-National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Adenine Phosphoribosyltransferase Deficiency
May 2013
Phase 4
NCT02338323
Shanghai 10th People's Hospital
Chronic Kidney Disease-Hyperuricemia-Abnormal Renal Function
January 2015
NCT02600780
Getz Pharma
Hyperuricemia
November 2013
Phase 4
NCT01101035
Takeda-Teijin America, Inc.
Cardiovascular Disease
April 2010
Phase 3
NCT00174915
Takeda
Gout
February 2003
Phase 3
NCT02944214
Shanghai 10th People's Hospital
Chronic Kidney Disease-Hyperuricemia-Abnormal Renal Function
October 2016
NCT00175019
Takeda
Gout
July 2003
Phase 3
NCT01077284
Takeda
Hyperuricosuria-Kidney Stones
February 2010
Phase 2
NCT03118739
AstraZeneca
Hyperuricemia-Albuminuria-Type 2 Diabetes
May 18, 2017
Phase 2
NCT02082769
Xijing Hospital-Qingdao Shengbang Pharmaceutical Co., Ltd.
Gout
July 2011
Phase 3
NCT00430248
Takeda
Gout
February 2007
Phase 3
NCT01736514
Astellas Pharma Taiwan, Inc.-Astellas Pharma Inc
Gout
March 2011
Phase 3
NCT02382640
Takeda
Healthy Volunteers
March 2015
Phase 1
NCT03149939
Benha University-New Jeddah Clinic Hospital
Hyperuricemia-Hemodialysis Complication
January 1, 2017
NCT01328769
Paul N. Hopkins-University of Utah
Hypertension
March 2011
Phase 4
NCT02866214
Ain Shams University
Endothelial Dysfunction-Endstage Renal Disease
August 2016
Phase 2-Phase 3
NCT02246673
Ardea Biosciences, Inc.
Gout
October 2014
Phase 2
NCT01416402
CymaBay Therapeutics, Inc.
Hyperuricemia-Gout
August 2011
Phase 2
NCT00821392
SK Chemicals Co.,Ltd.
Gout
August 2006
Phase 3
NCT02139046
Takeda
Gout
April 2014
Phase 3
NCT02128490
Takeda
Gout-Moderate Renal Impairment
May 2014
Phase 2
NCT02344602
University Health Network, Toronto-Canadian Institutes of Health Research (CIHR)-Toronto General Hospital-University of Toronto
Type 1 Diabetes Mellitus
December 2012
Phase 4
NCT02252835
CymaBay Therapeutics, Inc.
Gout-Hyperuricemia
August 2014
Phase 2
NCT03200210
Sun Yat-sen University
Hyperuricemia
July 2017
Phase 4
NCT02500641
Menarini International Operations Luxembourg SA
Gout
July 2015
Phase 4
NCT00174941
Takeda
Gout
March 2001
Phase 2
NCT00174967
Takeda
Gout
January 2001
Phase 2
NCT01510769
Ardea Biosciences, Inc.
Tophaceous Gout
January 2012
Phase 3
NCT02317861
AstraZeneca-Ardea Biosciences, Inc.
Gout and Asymptomatic Hyperuricemia
December 2014
Phase 1-Phase 2
NCT01654276
University of Texas Southwestern Medical Center
Gout
May 2012
Phase 4
NCT01112982
University of South Florida-Takeda Pharmaceuticals North America, Inc.
Gout
May 2010
Phase 4
NCT02060552
Tongji Hospital
Primary Gout
January 2013
Phase 4
NCT01712204
TWi Biotechnology, Inc.
Gout Flares
January 2013
Phase 2
NCT02287818
TWi Biotechnology, Inc.
Gout
December 2014